Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
Medical and pharmaceutical
Political and policy
World PD Day News
Resources and publications
Campaign success: NHS England to fund Duodopa
The NHS in England has announced they will fund Duodopa, a life-changing drug for people with advanced Parkinson's. This means that should a specialist Parkinson's clinician prescribe Duodopa, a person with Parkinson's will be able to receive it without delay.
02 July 2015
Herantis Pharma granted almost 3 million Euro government loan for Parkinson study
Tekes, the Finnish Funding Agency for Innovation, has granted a 2,903,000 EUR R&D loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson's disease. The loan was granted conditionally subject to obtaining regulatory approval for the clinical study.
30 June 2015
Diabetes drug found useless for Parkinson's
The diabetes drug pioglitazone (Actos) isn't likely to slow the progression of early Parkinson's disease, researchers reported. A futility study showed in several analyses that both doses of the drug that were tested (15 mg and 45 mg) were futile at slowing disease progression, Tanya Simuni, MD, of Northwestern University, and colleagues reported online in the Lancet Neurology.
28 June 2015
New study calls for partnering of Parkinson's research community with patient groups to improve effectiveness of clinical trials
Despite an urgent need for new medications, clinical trials in Parkinson's disease (PD) have a relatively low rate of success. The reasons for this are complex, prompting a group of investigators from PD advocacy groups to conduct a survey of the principle stakeholders, PD scientists, patients, and caregivers, to determine some of the underlying barriers.
25 June 2015
The London School of Economics (LSE) important research project exploring patients' & their caregivers' perceptions of health
The London School of Economics (LSE) is leading an EU-funded research project, Advance-HTA, looking at aspects of health technology assessment (a method used to determine where and how new treatments should be introduced into a national healthcare system).
24 June 2015
Impact of earlier use of NEUPRO (rotigotine transdermal patch) in Parkinson's disease patients discussed at first EAN congress
Results of the post-hoc analysis investigating the impact of 6-month earlier versus postponed initiation of NEUPRO (rotigotine transdermal patch) in patients with early-stage Parkinson's disease (PD) with mild symptom severity were presented during the UCB Neurology Corporate Satellite Symposium at the 1st Congress of the European Academy of Neurology (EAN), in Berlin.
23 June 2015
1 Hour More: A storytelling project to improve Parkinson's disease patients' quality of life
With the aim of raising public attention about Parkinson's disease (PD) at an international level, providing people with PD emotional and practical support, the European Parkinson's Disease Association (EPDA), in partnership with Zambon, an international pharmaceutical company strongly committed to the Central Nervous System (CNS) therapeutic area, has launched the storytelling project "1HourMore", during the 1st Congress of the European Academy of Neurology in Berlin.
22 June 2015
Parkinson disease appears associated with many cancers in Taiwan
Parkinson disease (PD) appeared associated with 16 types of cancer in a study in Taiwan, an effort to explain the association in an East Asian population because most prior research has been conducted in Western populations, according to an article published online by JAMA Oncology.
18 June 2015
NeuroDerm poster selected for blue ribbon highlights session during International Congress of Parkinson's & Movement disorders
NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that its poster presentation, "Stable levodopa plasma levels with ND0612 (LD/CD for subcutaneous infusion) in Parkinson's disease (PD) patients with motor fluctuations," has been selected as part of the 19th International Congress of Parkinson's Disease and Movement Disorders Blue Ribbon Highlights Session, which was held today in San Diego.
18 June 2015
UCB announces 1st presentation of data from NEUPRO Phase 3 study in China at international congress
UCB announced today efficacy and safety data from a Phase 3 study evaluating NEUPRO (rotigotine transdermal patch) in the treatment of patients in China with early-stage Parkinson's disease.
16 June 2015
Subscribe to this page >
Back to Top
Add page to PDF basket
Copyright © 2015 EPDA. All Rights Reserved.
Privacy and cookies